US FDA Approves Gilead Sciences Inc.’s Vemlidy to Treat Chronic Hepatitis B in Pediatric Patients
The US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy (tenofivir alafenamide) 25 mg tablets by Gilead Sciences, Inc., to treat chronic hepatitis B virus (HBV) in pediatric patients older than 12 years with compensated liver disease. Vemlidy is a targeted, novel prodrug of tenofovir, which was previously […]
Continue Reading